drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00214 | DB01082 | 1,028 | 1,448 | [
"DDInter1836",
"DDInter1713"
] | Torasemide | Streptomycin | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Major | 2 | [
[
[
1028,
25,
1448
]
],
[
[
1028,
21,
28680
],
[
28680,
60,
1448
]
],
[
[
1028,
25,
361
],
[
361,
24,
1448
]
],
[
[
1028,
24,
1215
],
[
12... | [
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
]
],
[
[
"Torasemide",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Torasemide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Streptomycin (Compound)
Torasemide may lead to a major life threatening interaction when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Torasemide may cause ... |
DB01764 | DB12332 | 805 | 1,619 | [
"DDInter469",
"DDInter1626"
] | Dalfopristin | Rucaparib | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
805,
24,
1619
]
],
[
[
805,
62,
222
],
[
222,
23,
1619
]
],
[
[
805,
25,
1135
],
[
1135,
23,
1619
]
],
[
[
805,
24,
309
],
[
309,
... | [
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Dalfopristin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Dalfopristin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a... |
DB00307 | DB00400 | 1,101 | 353 | [
"DDInter202",
"DDInter843"
] | Bexarotene | Griseofulvin | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Minor | 0 | [
[
[
1101,
23,
353
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
353
]
],
[
[
1101,
21,
28745
],
[
28745,
60,
353
]
],
[
[
1101,
62,
168
],
[
168,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Griseofulvin"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound)
Bexarotene (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Griseofulvin (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when take... |
DB00544 | DB08826 | 970 | 1,292 | [
"DDInter757",
"DDInter489"
] | Fluorouracil | Deferiprone | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
970,
25,
1292
]
],
[
[
970,
21,
28809
],
[
28809,
60,
1292
]
],
[
[
970,
63,
482
],
[
482,
25,
1292
]
],
[
[
970,
24,
1419
],
[
1419,
... | [
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Fluorouracil",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} ... | Fluorouracil (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Deferiprone (Compound)
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Fluor... |
DB00188 | DB08870 | 168 | 850 | [
"DDInter222",
"DDInter228"
] | Bortezomib | Brentuximab vedotin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
168,
24,
850
]
],
[
[
168,
24,
788
],
[
788,
24,
850
]
],
[
[
168,
24,
496
],
[
496,
63,
850
]
],
[
[
168,
23,
1671
],
[
1671,
2... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Hepatiti... |
DB08903 | DB12500 | 996 | 283 | [
"DDInter170",
"DDInter714"
] | Bedaquiline | Fedratinib | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
996,
24,
283
]
],
[
[
996,
25,
351
],
[
351,
23,
283
]
],
[
[
996,
64,
1593
],
[
1593,
23,
283
]
],
[
[
996,
63,
1419
],
[
1419,
... | [
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribocicl... | Bedaquiline may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Bedaquiline may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a minor interac... |
DB00595 | DB04398 | 1,545 | 193 | [
"DDInter1374",
"DDInter1015"
] | Oxytetracycline | Lactic acid | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste. It is produced by fermentation of a sugar source, such as ... | Moderate | 1 | [
[
[
1545,
24,
193
]
],
[
[
1545,
63,
663
],
[
663,
23,
193
]
],
[
[
1545,
40,
1620
],
[
1620,
24,
193
]
],
[
[
1545,
63,
663
],
[
663,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactic acid"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Lactic acid
Oxytetracycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate inter... |
DB08896 | DB12893 | 292 | 586 | [
"DDInter1576",
"DDInter1629"
] | Regorafenib | Sacituzumab govitecan | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab goviteca... | Major | 2 | [
[
[
292,
25,
586
]
],
[
[
292,
24,
384
],
[
384,
24,
586
]
],
[
[
292,
64,
4
],
[
4,
24,
586
]
],
[
[
292,
64,
1377
],
[
1377,
25,
... | [
[
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Regorafenib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccina... |
DB00078 | DB05679 | 1,172 | 1,683 | [
"DDInter898",
"DDInter1907"
] | Ibritumomab tiuxetan | Ustekinumab | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1172,
24,
1683
]
],
[
[
1172,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
1172,
25,
792
],
[
792,
63,
1683
]
],
[
[
1172,
25,
126
],
[
126,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olapar... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Rivaroxaban and Riv... |
DB00106 | DB01259 | 618 | 392 | [
"DDInter4",
"DDInter1024"
] | Abarelix | Lapatinib | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
618,
24,
392
]
],
[
[
618,
24,
479
],
[
479,
23,
392
]
],
[
[
618,
23,
112
],
[
112,
23,
392
]
],
[
[
618,
24,
898
],
[
898,
24,... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"D... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole ... |
DB00015 | DB15035 | 582 | 503 | [
"DDInter1585",
"DDInter1959"
] | Reteplase | Zanubrutinib | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
582,
25,
503
]
],
[
[
582,
24,
222
],
[
222,
24,
503
]
],
[
[
582,
25,
39
],
[
39,
25,
503
]
],
[
[
582,
24,
1018
],
[
1018,
25,... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Reteplase may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may ... |
DB00582 | DB01128 | 1,622 | 918 | [
"DDInter1946",
"DDInter204"
] | Voriconazole | Bicalutamide | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
1622,
24,
918
]
],
[
[
1622,
24,
129
],
[
129,
40,
918
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
918
]
],
[
[
1622,
21,
29666
],
[
29666,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Voriconazole (Compound) causes Melaena (Side Effect) a... |
DB00916 | DB04844 | 112 | 843 | [
"DDInter1202",
"DDInter1778"
] | Metronidazole | Tetrabenazine | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Minor | 0 | [
[
[
112,
23,
843
]
],
[
[
112,
63,
479
],
[
479,
40,
843
]
],
[
[
112,
21,
28698
],
[
28698,
60,
843
]
],
[
[
112,
63,
1555
],
[
1555,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
... | Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Metronidazole (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Tetrabenazine (Compound)
Metronidazole may cause a moderate i... |
DB00902 | DB04844 | 104 | 843 | [
"DDInter1168",
"DDInter1778"
] | Methdilazine | Tetrabenazine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Major | 2 | [
[
[
104,
25,
843
]
],
[
[
104,
63,
479
],
[
479,
40,
843
]
],
[
[
104,
23,
286
],
[
286,
63,
843
]
],
[
[
104,
63,
1594
],
[
1594,
2... | [
[
[
"Methdilazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Done... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Methdilazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate i... |
DB00254 | DB00754 | 964 | 157 | [
"DDInter598",
"DDInter696"
] | Doxycycline | Ethotoin | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
964,
24,
157
]
],
[
[
964,
24,
759
],
[
759,
40,
157
]
],
[
[
964,
24,
1096
],
[
1096,
62,
157
]
],
[
[
964,
24,
663
],
[
663,
2... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction t... |
DB00191 | DB01089 | 73 | 1,340 | [
"DDInter1447",
"DDInter502"
] | Phentermine | Deserpidine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Moderate | 1 | [
[
[
73,
24,
1340
]
],
[
[
73,
24,
1245
],
[
1245,
40,
1340
]
],
[
[
73,
24,
1445
],
[
1445,
24,
1340
]
],
[
[
73,
24,
1411
],
[
1411,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
],
[
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Deserpidine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction... |
DB01059 | DB01156 | 956 | 593 | [
"DDInter1313",
"DDInter252"
] | Norfloxacin | Bupropion | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
956,
25,
593
]
],
[
[
956,
6,
8374
],
[
8374,
45,
593
]
],
[
[
956,
21,
28757
],
[
28757,
60,
593
]
],
[
[
956,
23,
1532
],
[
1532,
... | [
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Norfloxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Buprop... | Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Norfloxacin (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide and Ifosf... |
DB01599 | DB08868 | 1,232 | 1,011 | [
"DDInter1523",
"DDInter737"
] | Probucol | Fingolimod | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1232,
25,
1011
]
],
[
[
1232,
62,
112
],
[
112,
23,
1011
]
],
[
[
1232,
24,
144
],
[
144,
63,
1011
]
],
[
[
1232,
63,
480
],
[
480,
... | [
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole... | Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodater... |
DB00374 | DB04865 | 1,061 | 4 | [
"DDInter1852",
"DDInter1335"
] | Treprostinil | Omacetaxine mepesuccinate | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
1061,
25,
4
]
],
[
[
1061,
7,
4811
],
[
4811,
46,
4
]
],
[
[
1061,
18,
7623
],
[
7623,
46,
4
]
],
[
[
1061,
18,
2389
],
[
2389,
... | [
[
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Treprostinil",
"{u} (Compound) upregulates {v} (Gene)",
"DUSP6"
],
[
"DUSP6",
"{u} (Gene) is upregulated by {v... | Treprostinil (Compound) upregulates DUSP6 (Gene) and DUSP6 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Treprostinil (Compound) downregulates RRP12 (Gene) and RRP12 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Treprostinil (Compound) downregulates CCDC85B (Gene) and CCDC85B (Gene) is d... |
DB00708 | DB01105 | 1,454 | 222 | [
"DDInter1718",
"DDInter1665"
] | Sufentanil | Sibutramine | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
1454,
25,
222
]
],
[
[
1454,
6,
8374
],
[
8374,
45,
222
]
],
[
[
1454,
21,
28921
],
[
28921,
60,
222
]
],
[
[
1454,
24,
384
],
[
384,
... | [
[
[
"Sufentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Sufentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sibutr... | Sufentanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Sufentanil (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sibutramine (Compound)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Id... |
DB00585 | DB00712 | 1,127 | 1,274 | [
"DDInter1309",
"DDInter763"
] | Nizatidine | Flurbiprofen | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Minor | 0 | [
[
[
1127,
23,
1274
]
],
[
[
1127,
23,
935
],
[
935,
63,
1274
]
],
[
[
1127,
7,
7720
],
[
7720,
45,
1274
]
],
[
[
1127,
7,
6855
],
[
6855,
... | [
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ketoprofen"
],
[
... | Nizatidine may cause a minor interaction that can limit clinical effects when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Nizatidine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Flurbiprofen (Compound)
Nizatidine (... |
DB00860 | DB01023 | 891 | 409 | [
"DDInter1513",
"DDInter716"
] | Prednisolone | Felodipine | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Moderate | 1 | [
[
[
891,
24,
409
]
],
[
[
891,
63,
376
],
[
376,
40,
409
]
],
[
[
891,
63,
1428
],
[
1428,
1,
409
]
],
[
[
891,
24,
336
],
[
336,
40... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Felodipine (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Felodipine (Compou... |
DB00470 | DB00996 | 530 | 1,198 | [
"DDInter601",
"DDInter791"
] | Dronabinol | Gabapentin | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to tr... | Moderate | 1 | [
[
[
530,
24,
1198
]
],
[
[
530,
21,
28676
],
[
28676,
60,
1198
]
],
[
[
530,
24,
1311
],
[
1311,
63,
1198
]
],
[
[
530,
63,
1594
],
[
1594... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Nervousness"
],
[
"Nervousness",
"{u} (Side Effect) is ... | Dronabinol (Compound) causes Nervousness (Side Effect) and Nervousness (Side Effect) is caused by Gabapentin (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00153 | DB00562 | 1,331 | 1,014 | [
"DDInter662",
"DDInter188"
] | Ergocalciferol | Benzthiazide | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Moderate | 1 | [
[
[
1331,
24,
1014
]
],
[
[
1331,
24,
811
],
[
811,
40,
1014
]
],
[
[
1331,
24,
674
],
[
674,
1,
1014
]
],
[
[
1331,
25,
1196
],
[
1196,
... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Benzthiazide (Compound)
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resemb... |
DB01267 | DB06699 | 519 | 774 | [
"DDInter1381",
"DDInter493"
] | Paliperidone | Degarelix | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
519,
24,
774
]
],
[
[
519,
63,
521
],
[
521,
1,
774
]
],
[
[
519,
21,
29232
],
[
29232,
60,
774
]
],
[
[
519,
62,
112
],
[
112,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Paliperidone (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Paliperidone may cause a minor interaction t... |
DB01610 | DB06650 | 248 | 1,500 | [
"DDInter1912",
"DDInter1324"
] | Valganciclovir | Ofatumumab | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Moderate | 1 | [
[
[
248,
24,
1500
]
],
[
[
248,
63,
869
],
[
869,
24,
1500
]
],
[
[
248,
24,
1362
],
[
1362,
63,
1500
]
],
[
[
248,
40,
563
],
[
563,
... | [
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
... | Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Ol... |
DB00582 | DB08865 | 1,622 | 1,593 | [
"DDInter1946",
"DDInter448"
] | Voriconazole | Crizotinib | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1622,
25,
1593
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1622,
21,
28792
],
[
28792,
60,
1593
]
],
[
[
1622,
25,
283
],
[
28... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cri... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Voriconazole (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Crizotinib (Compound)
Voriconazole may lead to a major life threatening interaction when taken w... |
DB00241 | DB00682 | 288 | 126 | [
"DDInter257",
"DDInter1951"
] | Butalbital | Warfarin | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
288,
25,
126
]
],
[
[
288,
24,
1376
],
[
1376,
40,
126
]
],
[
[
288,
62,
168
],
[
168,
23,
126
]
],
[
[
288,
24,
1053
],
[
1053,
... | [
[
[
"Butalbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenh... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Warfarin (Compound)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that ca... |
DB00959 | DB00976 | 1,486 | 1,056 | [
"DDInter1191",
"DDInter1758"
] | Methylprednisolone | Telithromycin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Major | 2 | [
[
[
1486,
25,
1056
]
],
[
[
1486,
6,
8374
],
[
8374,
45,
1056
]
],
[
[
1486,
21,
28681
],
[
28681,
60,
1056
]
],
[
[
1486,
40,
1220
],
[
1... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telithromycin"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Methylprednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Telithromycin (Compound)
Methylprednisolone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Telithromycin (Compound)
Methylprednisolone (Compound) resembles Dexamethasone (Compound) and Dexam... |
DB00443 | DB09065 | 251 | 760 | [
"DDInter195",
"DDInter424"
] | Betamethasone | Cobicistat | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
251,
24,
760
]
],
[
[
251,
63,
1101
],
[
1101,
23,
760
]
],
[
[
251,
24,
555
],
[
555,
23,
760
]
],
[
[
251,
62,
523
],
[
523,
2... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Ne... |
DB01125 | DB06779 | 279 | 365 | [
"DDInter98",
"DDInter470"
] | Anisindione | Dalteparin | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
279,
25,
365
]
],
[
[
279,
63,
305
],
[
305,
24,
365
]
],
[
[
279,
24,
1496
],
[
1496,
63,
365
]
],
[
[
279,
24,
1268
],
[
1268,
... | [
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
... | Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Anisindione may cause a moderate interaction that could exacerbate diseas... |
DB00163 | DB01206 | 1,461 | 37 | [
"DDInter1943",
"DDInter1086"
] | Vitamin E | Lomustine | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
1461,
24,
37
]
],
[
[
1461,
24,
147
],
[
147,
23,
37
]
],
[
[
1461,
24,
141
],
[
141,
24,
37
]
],
[
[
1461,
23,
259
],
[
259,
63... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomustine
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxurid... |
DB08865 | DB08870 | 1,593 | 850 | [
"DDInter448",
"DDInter228"
] | Crizotinib | Brentuximab vedotin | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1593,
24,
850
]
],
[
[
1593,
63,
788
],
[
788,
24,
850
]
],
[
[
1593,
64,
1570
],
[
1570,
24,
850
]
],
[
[
1593,
25,
1155
],
[
1155,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Crizotinib may lead to a major life threatening interaction when taken with Azithromycin and Azithr... |
DB00731 | DB00841 | 1,144 | 532 | [
"DDInter1269",
"DDInter577"
] | Nateglinide | Dobutamine | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Moderate | 1 | [
[
[
1144,
24,
532
]
],
[
[
1144,
24,
817
],
[
817,
40,
532
]
],
[
[
1144,
63,
1523
],
[
1523,
40,
532
]
],
[
[
1144,
24,
1052
],
[
1052,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Dobutamine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Dobutamine (Compound)
Nate... |
DB00220 | DB06626 | 798 | 263 | [
"DDInter1276",
"DDInter147"
] | Nelfinavir | Axitinib | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Major | 2 | [
[
[
798,
25,
263
]
],
[
[
798,
25,
1215
],
[
1215,
23,
263
]
],
[
[
798,
23,
752
],
[
752,
23,
263
]
],
[
[
798,
64,
837
],
[
837,
2... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u}... | Nelfinavir may lead to a major life threatening interaction when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a ... |
DB08913 | DB09330 | 1,186 | 985 | [
"DDInter1561",
"DDInter1352"
] | Radium Ra 223 dichloride | Osimertinib | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1186,
24,
985
]
],
[
[
1186,
63,
168
],
[
168,
23,
985
]
],
[
[
1186,
63,
134
],
[
134,
24,
985
]
],
[
[
1186,
24,
119
],
[
119,
... | [
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken... |
DB00761 | DB06212 | 1,621 | 165 | [
"DDInter1497",
"DDInter1833"
] | Potassium chloride | Tolvaptan | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
1621,
24,
165
]
],
[
[
1621,
21,
28829
],
[
28829,
60,
165
]
],
[
[
1621,
21,
28829
],
[
28829,
60,
1080
],
[
1080,
1,
165
]
],
[
[
16... | [
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Hyponatraemia"
],
[
"Hyponatraemia",
"{u... | Potassium chloride (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Tolvaptan (Compound)
Potassium chloride (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Conivaptan (Compound) and Conivaptan (Compound) resembles Tolvaptan (Compound)
... |
DB00775 | DB08918 | 1,226 | 41 | [
"DDInter1818",
"DDInter1059"
] | Tirofiban | Levomilnacipran | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
1226,
24,
41
]
],
[
[
1226,
24,
901
],
[
901,
40,
41
]
],
[
[
1226,
21,
28784
],
[
28784,
60,
41
]
],
[
[
1226,
25,
498
],
[
498,
... | [
[
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
... | Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Tirofiban (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Levomilnacipran (Compound)
Tirofiban may lead t... |
DB00529 | DB11901 | 789 | 913 | [
"DDInter779",
"DDInter107"
] | Foscarnet | Apalutamide | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
789,
24,
913
]
],
[
[
789,
23,
112
],
[
112,
23,
913
]
],
[
[
789,
63,
600
],
[
600,
24,
913
]
],
[
[
789,
24,
28
],
[
28,
24,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Foscarnet",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluc... |
DB00519 | DB00731 | 1,638 | 1,144 | [
"DDInter1843",
"DDInter1269"
] | Trandolapril | Nateglinide | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
1638,
35,
1144
]
],
[
[
1638,
1,
11483
],
[
11483,
40,
1144
]
],
[
[
1638,
1,
766
],
[
766,
1,
1144
]
],
[
[
1638,
1,
610
],
[
610,
... | [
[
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound)",
"Spirapril"
],
[
... | Trandolapril (Compound) resembles Nateglinide (Compound) and
Trandolapril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Nateglinide (Compound)
Trandolapril (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Nateglinide (Compound)
Trandolapril (Compound) resembles E... |
DB01142 | DB09080 | 1,264 | 144 | [
"DDInter593",
"DDInter1331"
] | Doxepin | Olodaterol | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1264,
24,
144
]
],
[
[
1264,
62,
1247
],
[
1247,
23,
144
]
],
[
[
1264,
63,
956
],
[
956,
24,
144
]
],
[
[
1264,
24,
371
],
[
371,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Doxepin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Nor... |
DB01100 | DB01619 | 1,568 | 830 | [
"DDInter1470",
"DDInter1441"
] | Pimozide | Phenindamine | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1568,
24,
830
]
],
[
[
1568,
24,
537
],
[
537,
40,
830
]
],
[
[
1568,
63,
1219
],
[
1219,
40,
830
]
],
[
[
1568,
63,
13
],
[
13,
... | [
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) resembles Phenindamine (Compound)
Pimo... |
DB00758 | DB04896 | 1,347 | 901 | [
"DDInter413",
"DDInter1220"
] | Clopidogrel | Milnacipran | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Moderate | 1 | [
[
[
1347,
24,
901
]
],
[
[
1347,
24,
41
],
[
41,
1,
901
]
],
[
[
1347,
63,
1349
],
[
1349,
40,
901
]
],
[
[
1347,
21,
28723
],
[
28723,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Meperidine and Meperidine (Compound) resembles Milnacipr... |
DB09074 | DB11952 | 1,362 | 800 | [
"DDInter1327",
"DDInter612"
] | Olaparib | Duvelisib | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
1362,
25,
800
]
],
[
[
1362,
63,
310
],
[
310,
24,
800
]
],
[
[
1362,
24,
270
],
[
270,
63,
800
]
],
[
[
1362,
64,
1419
],
[
1419,
... | [
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizu... |
DB00065 | DB00305 | 581 | 377 | [
"DDInter923",
"DDInter1232"
] | Infliximab | Mitomycin | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Major | 2 | [
[
[
581,
25,
377
]
],
[
[
581,
25,
450
],
[
450,
63,
377
]
],
[
[
581,
25,
552
],
[
552,
24,
377
]
],
[
[
581,
24,
987
],
[
987,
63,... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mitomycin"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
... | Infliximab may lead to a major life threatening interaction when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Infliximab may lead to a major life threatening interaction when taken with Carmustine and Carmustine may cause a mo... |
DB09280 | DB12887 | 1,604 | 1,598 | [
"DDInter1101",
"DDInter1750"
] | Lumacaftor | Tazemetostat | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Major | 2 | [
[
[
1604,
25,
1598
]
],
[
[
1604,
64,
168
],
[
168,
23,
1598
]
],
[
[
1604,
64,
594
],
[
594,
24,
1598
]
],
[
[
1604,
25,
985
],
[
985,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u}... | Lumacaftor may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Lumacaftor may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate intera... |
DB00916 | DB05316 | 112 | 749 | [
"DDInter1202",
"DDInter1467"
] | Metronidazole | Pimavanserin | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Minor | 0 | [
[
[
112,
23,
749
]
],
[
[
112,
63,
522
],
[
522,
24,
749
]
],
[
[
112,
23,
1264
],
[
1264,
24,
749
]
],
[
[
112,
62,
521
],
[
521,
2... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pimavanserin"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
... | Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Doxepin and D... |
DB00795 | DB09112 | 50 | 1,455 | [
"DDInter1725",
"DDInter1306"
] | Sulfasalazine | Nitrous acid | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Major | 2 | [
[
[
50,
25,
1455
]
],
[
[
50,
40,
161
],
[
161,
25,
1455
]
],
[
[
50,
64,
490
],
[
490,
25,
1455
]
],
[
[
50,
24,
587
],
[
587,
25,
... | [
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may lead to a major li... | Sulfasalazine (Compound) resembles Sulfadiazine (Compound) and Sulfadiazine may lead to a major life threatening interaction when taken with Nitrous acid
Sulfasalazine may lead to a major life threatening interaction when taken with Prilocaine and Prilocaine may lead to a major life threatening interaction when taken w... |
DB00242 | DB01005 | 1,064 | 995 | [
"DDInter392",
"DDInter894"
] | Cladribine | Hydroxyurea | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Major | 2 | [
[
[
1064,
25,
995
]
],
[
[
1064,
25,
1660
],
[
1660,
40,
995
]
],
[
[
1064,
5,
11555
],
[
11555,
44,
995
]
],
[
[
1064,
6,
4362
],
[
4362,... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetohydroxamic acid"
],
[
"Acetohydroxami... | Cladribine may lead to a major life threatening interaction when taken with Acetohydroxamic acid and Acetohydroxamic acid (Compound) resembles Hydroxyurea (Compound)
Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Hydroxyurea (Compound)
Cladribine (Compound) bind... |
DB00704 | DB00812 | 267 | 998 | [
"DDInter1263",
"DDInter1451"
] | Naltrexone | Phenylbutazone | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
267,
24,
998
]
],
[
[
267,
64,
576
],
[
576,
1,
998
]
],
[
[
267,
25,
704
],
[
704,
40,
998
]
],
[
[
267,
63,
362
],
[
362,
1,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methado... | Naltrexone may lead to a major life threatening interaction when taken with Methadone and Methadone (Compound) resembles Phenylbutazone (Compound)
Naltrexone may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Phenylbutazone (Compound)
Naltrexone may cause a moder... |
DB00321 | DB01246 | 21 | 820 | [
"DDInter78",
"DDInter45"
] | Amitriptyline | Alimemazine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
21,
35,
820
]
],
[
[
21,
1,
358
],
[
358,
24,
820
]
],
[
[
21,
24,
104
],
[
104,
40,
820
]
],
[
[
21,
1,
11275
],
[
11275,
40,
... | [
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
... | Amitriptyline (Compound) resembles Alimemazine (Compound) and
Amitriptyline (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00770 | DB01088 | 642 | 714 | [
"DDInter55",
"DDInter908"
] | Alprostadil | Iloprost | Alprostadil is a chemically-identical synthetic form of prostaglandin E1 (PGE1), a potent vasodilator produced endogenously. In 1996, the FDA approved the use of alprostadil, administered either with an intracavernosal injection or an intraurethral suppository, for the treatment of erectile dysfunction, and it is used ... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
642,
24,
714
]
],
[
[
642,
6,
1946
],
[
1946,
45,
714
]
],
[
[
642,
24,
1450
],
[
1450,
63,
714
]
],
[
[
642,
6,
9885
],
[
9885,
... | [
[
[
"Alprostadil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Alprostadil",
"{u} (Compound) binds {v} (Gene)",
"PTGIR"
],
[
"PTGIR",
"{u} (Gene) is bound by {v} (Compound)",
... | Alprostadil (Compound) binds PTGIR (Gene) and PTGIR (Gene) is bound by Iloprost (Compound)
Alprostadil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Alprostadil (Com... |
DB01142 | DB01156 | 1,264 | 593 | [
"DDInter593",
"DDInter252"
] | Doxepin | Bupropion | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
1264,
25,
593
]
],
[
[
1264,
6,
8374
],
[
8374,
45,
593
]
],
[
[
1264,
21,
29243
],
[
29243,
60,
593
]
],
[
[
1264,
63,
752
],
[
752,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bupropion"
... | Doxepin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Doxepin (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Bupropion (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may ca... |
DB00333 | DB01612 | 576 | 1,637 | [
"DDInter1166",
"DDInter92"
] | Methadone | Amyl Nitrite | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
576,
24,
1637
]
],
[
[
576,
1,
358
],
[
358,
24,
1637
]
],
[
[
576,
64,
475
],
[
475,
24,
1637
]
],
[
[
576,
36,
401
],
[
401,
2... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a mod... | Methadone (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Methadone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate dis... |
DB01261 | DB01309 | 170 | 1,254 | [
"DDInter1679",
"DDInter933"
] | Sitagliptin | Insulin glulisine | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
170,
24,
1254
]
],
[
[
170,
62,
1103
],
[
1103,
23,
1254
]
],
[
[
170,
24,
1033
],
[
1033,
63,
1254
]
],
[
[
170,
63,
167
],
[
167,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
... | Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Al... |
DB00816 | DB01118 | 1,674 | 33 | [
"DDInter1346",
"DDInter76"
] | Orciprenaline | Amiodarone | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Major | 2 | [
[
[
1674,
25,
33
]
],
[
[
1674,
25,
540
],
[
540,
1,
33
]
],
[
[
1674,
18,
16549
],
[
16549,
46,
33
]
],
[
[
1674,
21,
28779
],
[
28779,
... | [
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
... | Orciprenaline may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Orciprenaline (Compound) downregulates SLC2A6 (Gene) and SLC2A6 (Gene) is upregulated by Amiodarone (Compound)
Orciprenaline (Compound) causes Dry mouth (Side Effect) and... |
DB01206 | DB09074 | 37 | 1,362 | [
"DDInter1086",
"DDInter1327"
] | Lomustine | Olaparib | An alkylating agent of value against both hematologic malignancies and solid tumors. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
37,
24,
1362
]
],
[
[
37,
63,
896
],
[
896,
24,
1362
]
],
[
[
37,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
37,
74,
552
],
[
552,
24... | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"... | Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab... |
DB00594 | DB01069 | 863 | 401 | [
"DDInter68",
"DDInter1533"
] | Amiloride | Promethazine | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
863,
24,
401
]
],
[
[
863,
24,
1264
],
[
1264,
63,
401
]
],
[
[
863,
24,
104
],
[
104,
24,
401
]
],
[
[
863,
21,
28709
],
[
28709,
... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazi... |
DB00801 | DB11130 | 1,563 | 407 | [
"DDInter850",
"DDInter1344"
] | Halazepam | Opium | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1563,
24,
407
]
],
[
[
1563,
63,
662
],
[
662,
24,
407
]
],
[
[
1563,
24,
849
],
[
849,
24,
407
]
],
[
[
1563,
1,
481
],
[
481,
... | [
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyram... |
DB12457 | DB13874 | 1,180 | 1,501 | [
"DDInter1598",
"DDInter639"
] | Rimegepant | Enasidenib | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
1180,
24,
1501
]
],
[
[
1180,
63,
1619
],
[
1619,
24,
1501
]
],
[
[
1180,
64,
1604
],
[
1604,
24,
1501
]
],
[
[
1180,
63,
1619
],
[
16... | [
[
[
"Rimegepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Rimegepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Rimegepant may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Rimegepant may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a ... |
DB01009 | DB01105 | 935 | 222 | [
"DDInter1009",
"DDInter1665"
] | Ketoprofen | Sibutramine | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
935,
24,
222
]
],
[
[
935,
18,
7359
],
[
7359,
57,
222
]
],
[
[
935,
21,
29356
],
[
29356,
60,
222
]
],
[
[
935,
24,
384
],
[
384,
... | [
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Ketoprofen",
"{u} (Compound) downregulates {v} (Gene)",
"TXNDC9"
],
[
"TXNDC9",
"{u} (Gene) is downregulated by... | Ketoprofen (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Sibutramine (Compound)
Ketoprofen (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Sibutramine (Compound)
Ketoprofen may cause a moderate interaction that could exacerbat... |
DB01076 | DB11967 | 700 | 710 | [
"DDInter133",
"DDInter210"
] | Atorvastatin | Binimetinib | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
700,
24,
710
]
],
[
[
700,
24,
1593
],
[
1593,
24,
710
]
],
[
[
700,
24,
1619
],
[
1619,
63,
710
]
],
[
[
700,
63,
467
],
[
467,
... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ru... |
DB00188 | DB00731 | 168 | 1,144 | [
"DDInter222",
"DDInter1269"
] | Bortezomib | Nateglinide | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
168,
24,
1144
]
],
[
[
168,
40,
11242
],
[
11242,
40,
1144
]
],
[
[
168,
6,
6017
],
[
6017,
45,
1144
]
],
[
[
168,
21,
28787
],
[
2878... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Bortezomib",
"{u} (Compound) resembles {v} (Compound)",
"Aspartame"
],
[
"Aspartame",
"{u} (Compound) resembles... | Bortezomib (Compound) resembles Aspartame (Compound) and Aspartame (Compound) resembles Nateglinide (Compound)
Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nateglinide (Compound)
Bortezomib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compo... |
DB00197 | DB01072 | 1,324 | 915 | [
"DDInter1881",
"DDInter129"
] | Troglitazone | Atazanavir | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Moderate | 1 | [
[
[
1324,
24,
915
]
],
[
[
1324,
24,
1327
],
[
1327,
1,
915
]
],
[
[
1324,
23,
1101
],
[
1101,
24,
915
]
],
[
[
1324,
63,
168
],
[
168,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that cou... |
DB00331 | DB00814 | 1,645 | 1,171 | [
"DDInter1164",
"DDInter1143"
] | Metformin | Meloxicam | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
1645,
24,
1171
]
],
[
[
1645,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
1645,
21,
28997
],
[
28997,
60,
1171
]
],
[
[
1645,
63,
1560
],
[
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Metformin (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Meloxicam (Compound)
Metformin may cause a modera... |
DB01284 | DB10989 | 1,042 | 496 | [
"DDInter1782",
"DDInter858"
] | Tetracosactide | Hepatitis A Vaccine | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1042,
24,
496
]
],
[
[
1042,
24,
4
],
[
4,
24,
496
]
],
[
[
1042,
25,
976
],
[
976,
24,
496
]
],
[
[
1042,
63,
589
],
[
589,
24,... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxin... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Tetracosactide may lead to a major life threatening interaction when ... |
DB01169 | DB04868 | 57 | 478 | [
"DDInter120",
"DDInter1293"
] | Arsenic trioxide | Nilotinib | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
57,
25,
478
]
],
[
[
57,
6,
4973
],
[
4973,
45,
478
]
],
[
[
57,
6,
1990
],
[
1990,
46,
478
]
],
[
[
57,
62,
1247
],
[
1247,
23,... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Arsenic trioxide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Arsenic trioxide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Arsenic trioxide (Compound) binds JUN (Gene) and JUN (Gene) is upregulated by Nilotinib (Compound)
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamet... |
DB00843 | DB00902 | 479 | 104 | [
"DDInter583",
"DDInter1168"
] | Donepezil | Methdilazine | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
479,
24,
104
]
],
[
[
479,
63,
13
],
[
13,
24,
104
]
],
[
[
479,
24,
820
],
[
820,
1,
104
]
],
[
[
479,
24,
537
],
[
537,
40,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine a... |
DB01166 | DB08864 | 477 | 786 | [
"DDInter379",
"DDInter1595"
] | Cilostazol | Rilpivirine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
477,
24,
786
]
],
[
[
477,
24,
655
],
[
655,
1,
786
]
],
[
[
477,
6,
8374
],
[
8374,
45,
786
]
],
[
[
477,
21,
29343
],
[
29343,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Cilostazol (Compound) causes Blood creatinine increased (Side Ef... |
DB11703 | DB15233 | 405 | 1,650 | [
"DDInter9",
"DDInter142"
] | Acalabrutinib | Avapritinib | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
405,
25,
1650
]
],
[
[
405,
63,
1478
],
[
1478,
24,
1650
]
],
[
[
405,
24,
159
],
[
159,
24,
1650
]
],
[
[
405,
64,
908
],
[
908,
... | [
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivac... | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib an... |
DB01126 | DB11986 | 1,260 | 484 | [
"DDInter611",
"DDInter648"
] | Dutasteride | Entrectinib | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestos... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1260,
24,
484
]
],
[
[
1260,
24,
1478
],
[
1478,
24,
484
]
],
[
[
1260,
24,
159
],
[
159,
63,
484
]
],
[
[
1260,
63,
752
],
[
752,
... | [
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and La... |
DB00357 | DB11791 | 1,051 | 785 | [
"DDInter71",
"DDInter287"
] | Aminoglutethimide | Capmatinib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
1051,
24,
785
]
],
[
[
1051,
24,
1135
],
[
1135,
23,
785
]
],
[
[
1051,
24,
868
],
[
868,
24,
785
]
],
[
[
1051,
24,
1320
],
[
1320,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib... |
DB00374 | DB00692 | 1,061 | 274 | [
"DDInter1852",
"DDInter1448"
] | Treprostinil | Phentolamine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Moderate | 1 | [
[
[
1061,
24,
274
]
],
[
[
1061,
18,
16662
],
[
16662,
46,
274
]
],
[
[
1061,
21,
29118
],
[
29118,
60,
274
]
],
[
[
1061,
24,
572
],
[
57... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Treprostinil",
"{u} (Compound) downregulates {v} (Gene)",
"SQRDL"
],
[
"SQRDL",
"{u} (Gene) is upregulated b... | Treprostinil (Compound) downregulates SQRDL (Gene) and SQRDL (Gene) is upregulated by Phentolamine (Compound)
Treprostinil (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Phentolamine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when take... |
DB00910 | DB11952 | 1,041 | 800 | [
"DDInter1394",
"DDInter612"
] | Paricalcitol | Duvelisib | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
1041,
24,
800
]
],
[
[
1041,
24,
1017
],
[
1017,
63,
800
]
],
[
[
1041,
24,
351
],
[
351,
24,
800
]
],
[
[
1041,
24,
609
],
[
609,
... | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[... | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Rib... |
DB00757 | DB00862 | 1,166 | 1,005 | [
"DDInter581",
"DDInter1918"
] | Dolasetron | Vardenafil | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Major | 2 | [
[
[
1166,
25,
1005
]
],
[
[
1166,
6,
8374
],
[
8374,
45,
1005
]
],
[
[
1166,
21,
28770
],
[
28770,
60,
1005
]
],
[
[
1166,
23,
112
],
[
11... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vardenafil"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vardena... | Dolasetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vardenafil (Compound)
Dolasetron (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Vardenafil (Compound)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and M... |
DB09115 | DB11989 | 505 | 1,434 | [
"DDInter559",
"DDInter183"
] | Diiodohydroxyquinoline | Benznidazole | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
505,
24,
1434
]
],
[
[
505,
63,
375
],
[
375,
24,
1434
]
],
[
[
505,
24,
116
],
[
116,
24,
1434
]
],
[
[
505,
24,
148
],
[
148,
... | [
[
[
"Diiodohydroxyquinoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Diiodohydroxyquinoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"C... | Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate dise... |
DB00741 | DB14443 | 167 | 987 | [
"DDInter885",
"DDInter1931"
] | Hydrocortisone | Vibrio cholerae CVD 103-HgR strain live antigen | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
167,
24,
987
]
],
[
[
167,
1,
1220
],
[
1220,
24,
987
]
],
[
[
167,
24,
351
],
[
351,
24,
987
]
],
[
[
167,
63,
305
],
[
305,
24... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
... | Hydrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Rib... |
DB00427 | DB11601 | 1,233 | 1,270 | [
"DDInter1879",
"DDInter1889"
] | Triprolidine | Tuberculin purified protein derivative | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1233,
24,
1270
]
],
[
[
1233,
24,
13
],
[
13,
24,
1270
]
],
[
[
1233,
63,
1242
],
[
1242,
24,
1270
]
],
[
[
1233,
24,
13
],
[
13,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Triprolidine may cause a moderate interaction that could exacerbate diseas... |
DB00226 | DB11827 | 1,000 | 433 | [
"DDInter845",
"DDInter669"
] | Guanadrel | Ertugliflozin | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1000,
24,
433
]
],
[
[
1000,
24,
959
],
[
959,
24,
433
]
],
[
[
1000,
63,
73
],
[
73,
24,
433
]
],
[
[
1000,
24,
1019
],
[
1019,
... | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phente... |
DB00280 | DB00757 | 494 | 1,166 | [
"DDInter575",
"DDInter581"
] | Disopyramide | Dolasetron | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
494,
25,
1166
]
],
[
[
494,
24,
19
],
[
19,
40,
1166
]
],
[
[
494,
24,
85
],
[
85,
1,
1166
]
],
[
[
494,
6,
8374
],
[
8374,
45,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyosc... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Dolasetron (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Dolasetron (Compound... |
DB00322 | DB01041 | 141 | 770 | [
"DDInter742",
"DDInter1789"
] | Floxuridine | Thalidomide | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
141,
25,
770
]
],
[
[
141,
7,
7720
],
[
7720,
45,
770
]
],
[
[
141,
7,
2900
],
[
2900,
46,
770
]
],
[
[
141,
21,
29425
],
[
29425,
... | [
[
[
"Floxuridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Floxuridine",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"... | Floxuridine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Thalidomide (Compound)
Floxuridine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Thalidomide (Compound)
Floxuridine (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is cause... |
DB00213 | DB00227 | 837 | 1,463 | [
"DDInter1388",
"DDInter1098"
] | Pantoprazole | Lovastatin | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Moderate | 1 | [
[
[
837,
24,
1463
]
],
[
[
837,
6,
6017
],
[
6017,
45,
1463
]
],
[
[
837,
21,
28748
],
[
28748,
60,
1463
]
],
[
[
837,
24,
1152
],
[
1152,... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
]
],
[
[
"Pantoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compoun... | Pantoprazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Lovastatin (Compound)
Pantoprazole (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Lovastatin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and ... |
DB01181 | DB09135 | 1,532 | 1,211 | [
"DDInter906",
"DDInter967"
] | Ifosfamide | Ioxilan | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
1532,
25,
1211
]
],
[
[
1532,
63,
1648
],
[
1648,
24,
1211
]
],
[
[
1532,
24,
242
],
[
242,
63,
1211
]
],
[
[
1532,
63,
372
],
[
372,
... | [
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin"... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesi... |
DB08881 | DB09075 | 868 | 498 | [
"DDInter1925",
"DDInter621"
] | Vemurafenib | Edoxaban | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
868,
25,
498
]
],
[
[
868,
63,
109
],
[
109,
24,
498
]
],
[
[
868,
24,
321
],
[
321,
63,
498
]
],
[
[
868,
64,
1237
],
[
1237,
2... | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selum... |
DB08889 | DB09498 | 350 | 810 | [
"DDInter299",
"DDInter1715"
] | Carfilzomib | Strontium chloride Sr-89 | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
350,
24,
810
]
],
[
[
350,
63,
1555
],
[
1555,
24,
810
]
],
[
[
350,
24,
1060
],
[
1060,
63,
810
]
],
[
[
350,
24,
1362
],
[
1362,
... | [
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Enf... |
DB00197 | DB00496 | 1,324 | 194 | [
"DDInter1881",
"DDInter480"
] | Troglitazone | Darifenacin | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Moderate | 1 | [
[
[
1324,
24,
194
]
],
[
[
1324,
24,
704
],
[
704,
1,
194
]
],
[
[
1324,
24,
1213
],
[
1213,
63,
194
]
],
[
[
1324,
24,
883
],
[
883,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Darifenacin (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could ... |
DB00414 | DB01267 | 590 | 519 | [
"DDInter16",
"DDInter1381"
] | Acetohexamide | Paliperidone | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
590,
24,
519
]
],
[
[
590,
24,
1664
],
[
1664,
1,
519
]
],
[
[
590,
24,
135
],
[
135,
63,
519
]
],
[
[
590,
24,
1148
],
[
1148,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a moderate interactio... |
DB11901 | DB14723 | 913 | 159 | [
"DDInter107",
"DDInter1026"
] | Apalutamide | Larotrectinib | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resi... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Major | 2 | [
[
[
913,
25,
159
]
],
[
[
913,
25,
907
],
[
907,
23,
159
]
],
[
[
913,
63,
479
],
[
479,
23,
159
]
],
[
[
913,
64,
318
],
[
318,
23,... | [
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"... | Apalutamide may lead to a major life threatening interaction when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause... |
DB00384 | DB01222 | 1,275 | 617 | [
"DDInter1859",
"DDInter246"
] | Triamterene | Budesonide | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1275,
24,
617
]
],
[
[
1275,
24,
251
],
[
251,
1,
617
]
],
[
[
1275,
18,
2201
],
[
2201,
57,
617
]
],
[
[
1275,
21,
28680
],
[
28680,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Triamterene (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Budesonide (Compound)
Triamterene (Compound) causes Rash (Side... |
DB00701 | DB06626 | 1,091 | 263 | [
"DDInter90",
"DDInter147"
] | Amprenavir | Axitinib | Amprenavir is a protease inhibitor used to treat HIV infection. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Major | 2 | [
[
[
1091,
25,
263
]
],
[
[
1091,
24,
1475
],
[
1475,
62,
263
]
],
[
[
1091,
62,
752
],
[
752,
23,
263
]
],
[
[
1091,
24,
1283
],
[
1283,
... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
],
[
"Sodium c... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may cause a minor interaction that can limit clinical effects when taken with Axitinib
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cime... |
DB01045 | DB12141 | 463 | 971 | [
"DDInter1590",
"DDInter817"
] | Rifampicin | Gilteritinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
463,
25,
971
]
],
[
[
463,
25,
1135
],
[
1135,
23,
971
]
],
[
[
463,
25,
466
],
[
466,
62,
971
]
],
[
[
463,
63,
112
],
[
112,
2... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Rifampicin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Rifampicin may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor inter... |
DB00242 | DB05239 | 1,064 | 866 | [
"DDInter392",
"DDInter425"
] | Cladribine | Cobimetinib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Major | 2 | [
[
[
1064,
25,
866
]
],
[
[
1064,
25,
482
],
[
482,
24,
866
]
],
[
[
1064,
24,
785
],
[
785,
63,
866
]
],
[
[
1064,
24,
336
],
[
336,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} ... | Cladribine may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib and Capmatinib may cause... |
DB00401 | DB00959 | 84 | 1,486 | [
"DDInter1298",
"DDInter1191"
] | Nisoldipine | Methylprednisolone | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
84,
24,
1486
]
],
[
[
84,
24,
175
],
[
175,
40,
1486
]
],
[
[
84,
24,
167
],
[
167,
1,
1486
]
],
[
[
84,
6,
8374
],
[
8374,
45,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resemble... |
DB00104 | DB00834 | 966 | 932 | [
"DDInter1323",
"DDInter1215"
] | Octreotide | Mifepristone | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Moderate | 1 | [
[
[
966,
24,
932
]
],
[
[
966,
21,
28762
],
[
28762,
60,
932
]
],
[
[
966,
25,
1101
],
[
1101,
23,
932
]
],
[
[
966,
24,
1017
],
[
1017,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Octreotide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caus... | Octreotide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Mifepristone (Compound)
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mifepristone
Octreotide ... |
DB00387 | DB01246 | 1,386 | 820 | [
"DDInter1528",
"DDInter45"
] | Procyclidine | Alimemazine | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1386,
24,
820
]
],
[
[
1386,
24,
104
],
[
104,
40,
820
]
],
[
[
1386,
24,
401
],
[
401,
24,
820
]
],
[
[
1386,
24,
649
],
[
649,
... | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interacti... |
DB00398 | DB14761 | 79 | 242 | [
"DDInter1702",
"DDInter1578"
] | Sorafenib | Remdesivir | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
79,
24,
242
]
],
[
[
79,
25,
1377
],
[
1377,
24,
242
]
],
[
[
79,
24,
129
],
[
129,
24,
242
]
],
[
[
79,
63,
482
],
[
482,
24,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide... | Sorafenib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may ca... |
DB00397 | DB13928 | 1,466 | 1,385 | [
"DDInter1458",
"DDInter1660"
] | Phenylpropanolamine | Semaglutide | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1466,
24,
1385
]
],
[
[
1466,
24,
280
],
[
280,
24,
1385
]
],
[
[
1466,
35,
1445
],
[
1445,
24,
1385
]
],
[
[
1466,
64,
73
],
[
73,
... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephente... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Phenylpropanolamine (Compound) resembles Pseudoephedrine (Compound) and Phenylpropanolamine may ... |
DB00214 | DB09020 | 1,028 | 28 | [
"DDInter1836",
"DDInter212"
] | Torasemide | Bisacodyl | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1028,
24,
28
]
],
[
[
1028,
18,
13183
],
[
13183,
57,
28
]
],
[
[
1028,
21,
28809
],
[
28809,
60,
28
]
],
[
[
1028,
24,
870
],
[
870,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Torasemide",
"{u} (Compound) downregulates {v} (Gene)",
"POLG2"
],
[
"POLG2",
"{u} (Gene) is downregulated by {v}... | Torasemide (Compound) downregulates POLG2 (Gene) and POLG2 (Gene) is downregulated by Bisacodyl (Compound)
Torasemide (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacodyl (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Fludroc... |
DB00176 | DB06081 | 529 | 1,046 | [
"DDInter770",
"DDInter286"
] | Fluvoxamine | Caplacizumab | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Moderate | 1 | [
[
[
529,
24,
1046
]
],
[
[
529,
25,
1039
],
[
1039,
24,
1046
]
],
[
[
529,
24,
885
],
[
885,
24,
1046
]
],
[
[
529,
24,
1479
],
[
1479,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"D... | Fluvoxamine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epopr... |
DB01610 | DB15091 | 248 | 676 | [
"DDInter1912",
"DDInter1901"
] | Valganciclovir | Upadacitinib | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
248,
24,
676
]
],
[
[
248,
40,
563
],
[
563,
24,
676
]
],
[
[
248,
63,
597
],
[
597,
24,
676
]
],
[
[
248,
24,
810
],
[
810,
24,... | [
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Valganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cau... | Valganciclovir (Compound) resembles Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.